Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Sophie Miriam Lanzkron, MD
Healthcare Provider Director of Sickle Cell Center for Adults
The Johns Hopkins Hospital
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, Maryland, United States
Dr. Sophie Lanzkron is an associate professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hematology and sickle cell disease. Dr. Lanzkron is director of the Sickle Cell Center for Adults at Johns Hopkins. Dr. Lanzkron received her undergraduate degree in biology from Brandeis University. She earned her M.D. from Albert Einstein College of Medicine. She completed her residency at the University of Maryland Medical Center and performed her fellowship in hematology at Johns Hopkins. She joined the faculty of Johns Hopkins in 2000.
Dr. Lanzkron’s major clinical research involves the study of sickle cell disease. Her primary research interest is to understand the barriers to care for adults with sickle cell disease. In 1998, the FDA approved the use of hydroxyurea to treat patients with sickle cell disease. This approval was based on a large clinical trial centered at Johns Hopkins. The use of hydroxyurea was predicted to decrease hospitalizations and the costs of care for those with sickle cell disease. Dr. Lanzkron’s research has shown that despite the approval of hydroxyurea, the costs of caring for patients with sickle cell disease have increased significantly over the last seven years. Research is ongoing to identify the factors that limit access to care for this population.
Representative Publications:
Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease
Related Content
-
Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crisesObjective: Growing literature has docum...
-
Nadine Matthie, PhD, RNNadine Matthie is an assistant professor...
-
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-bas...The clinical efficacy of hydroxyurea in ...
-
Jerlym S. Porter, PhD, MPHJerlym S. Porter is an Associate Member ...
-
UConn Health / New England Sickle Cell InstituteThe New England Sickle Cell Institute at...
-
Cohen Children’s Medical Center Northwell HealthThe mission of the Sickle Cell Program a...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
+myBinder